Barclays Issues Positive Forecast for Thermo Fisher Scientific (NYSE:TMO) Stock Price

Key Points

• Barclays has raised its price target for Thermo Fisher Scientific from $585 to $625, indicating a potential upside of 9.95%.
• Analysts from other firms, including JPMorgan Chase and Royal Bank of Canada, have also given positive ratings with target prices ranging from $561 to $650.
• Thermo Fisher Scientific recently reported quarterly earnings of $5.79 per share, beating estimates and showing a revenue increase of 4.9% compared to the same quarter last year.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price objective hoisted by research analysts at Barclays from $585.00 to $625.00 in a research note issued on Thursday, Marketbeat reports. The firm presently has an "overweight" rating on the medical research company's stock. Barclays's price target indicates a potential upside of 9.95% from the stock's current price.

Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. HSBC reaffirmed a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Leerink Partners upped their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, Citigroup raised their price target on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a "neutral" rating in a report on Thursday. Sixteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $584.26.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $568.42 on Thursday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $214.64 billion, a PE ratio of 32.88, a price-to-earnings-growth ratio of 3.22 and a beta of 0.77. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $610.97. The firm's 50-day simple moving average is $500.65 and its two-hundred day simple moving average is $451.30.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts predict that Thermo Fisher Scientific will post 23.28 earnings per share for the current year.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last quarter. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after buying an additional 877 shares during the period. Consolidated Portfolio Review Corp lifted its stake in shares of Thermo Fisher Scientific by 9.1% in the 1st quarter. Consolidated Portfolio Review Corp now owns 683 shares of the medical research company's stock valued at $340,000 after acquiring an additional 57 shares during the last quarter. Finally, Strategic Investment Advisors MI grew its position in Thermo Fisher Scientific by 17.3% during the 1st quarter. Strategic Investment Advisors MI now owns 1,005 shares of the medical research company's stock worth $500,000 after acquiring an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.